Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Tonix Licenses Intranasal Treatment Technology From Inserm

Tonix Pharmaceuticals has licensed technology from the French National Institute of Health and Medical Research (Inserm) that it aims to use for treating failure to thrive in Prader-Willi syndrome. The license will allow Tonix to expand its intranasal — administered via the nose — potentiated oxytocin program to…

INV-101 Granted FDA Rare Pediatric Disease Designation

Inversago Pharma‘s INV-101 has been granted rare pediatric disease (RPD) designation by the U.S. Food and Drug Administration for the treatment of Prader-Willi syndrome (PWS). This designation is given to potential medications targeting serious diseases that primarily affect less than 200,000 Americans ages 18 or younger. If the…

FPWR Awards More Than $900,000 to Nine Grants in PWS

The Foundation for Prader-Willi Research (FPWR) is funding nine projects that intend to improve understanding and help find treatments, including gene therapies, for Prader-Willi syndrome (PWS). In total, FPWR awarded a total of $912,251 in the first round of this year’s research awards, according to a press release.